WASHINGTON — The Centers for Medicare and Medicaid Services ended a plan to pay for a $475,000 Novartis cancer drug based on whether it actually helped patients because the government didn’t think the program would work, the CMS administrator said Thursday.

“We didn’t think it would be successful as proposed,” Seema Verma said at an event for journalists, in her first public explanation of the CMS decision. “So, we’re moving in a different direction.” She did not specify what the new direction is.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy